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Abstract
Background: Schizophrenia is a highly heritable, neuropsychiatric disorder characterized by episodic psychosis
and altered cognitive function. Despite success in identifying genetic variants associated with schizophrenia,
there remains uncertainty about the causal genes involved in disease pathogenesis and how their function is
regulated.
Results: We performed a multi-stage epigenome-wide association study, quantifying genome-wide patterns of
DNA methylation in a total of 1714 individuals from three independent sample cohorts. We have identified
multiple differentially methylated positions and regions consistently associated with schizophrenia across the
three cohorts; these effects are independent of important confounders such as smoking. We also show that
epigenetic variation at multiple loci across the genome contributes to the polygenic nature of schizophrenia.
Finally, we show how DNA methylation quantitative trait loci in combination with Bayesian co-localization
analyses can be used to annotate extended genomic regions nominated by studies of schizophrenia, and to
identify potential regulatory variation causally involved in disease.
Conclusions: This study represents the first systematic integrated analysis of genetic and epigenetic variation
in schizophrenia, introducing a methodological approach that can be used to inform epigenome-wide
association study analyses of other complex traits and diseases. We demonstrate the utility of using a
polygenic risk score to identify molecular variation associated with etiological variation, and of using DNA methylation
quantitative trait loci to refine the functional and regulatory variation associated with schizophrenia risk variants. Finally,
we present strong evidence for the co-localization of genetic associations for schizophrenia and differential DNA
methylation.
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Background
Schizophrenia is a severe, highly heritable, neuropsychi-
atric disorder characterized by episodic psychosis and
altered cognitive function. With a lifetime prevalence
rate of ~1 %, schizophrenia contributes significantly to
the global burden of disease, ranking amongst the top 10
causes of disability in developed countries worldwide [1].
Schizophrenia has a highly complex etiology, aggregating
in families but not segregating in a Mendelian manner.
Recent approaches to understanding the causes of schizo-
phrenia have focused on describing the genetic contribu-
tion to the disorder; the advent of large-scale genome-wide
association studies (GWAS) and exome sequencing has
enabled a systematic, hypothesis-free exploration of gen-
etic risk factors. These “forward-genetics” approaches have
been highly successful; a recent large-scale GWAS meta-
analysis by the Psychiatric Genomics Consortium (PGC)
identified 108 independent genomic loci exhibiting a
genome-wide significant association with schizophrenia
(P < 5 × 10−8), with evidence for a substantial polygenic
component in signals that fall below this stringent level of
significance [2].
Despite success in identifying genetic variants associated
with schizophrenia, however, there remains uncertainty
about the causal genes involved in disease pathogenesis,
and how their function is regulated. Many GWAS variants
reside in large regions of strong linkage disequilibrium
(LD) and do not directly index coding changes affecting
protein structure [3]; instead, they are hypothesized to in-
fluence gene regulation, a hypothesis supported by the
observation that common variants associated with disease
are enriched in regulatory domains, including enhancers
and regions of open chromatin [4, 5]. Insights into the
functional complexity of the genome have also focused
attention on the probable role of non-sequence-based
genomic variation in health and disease. Of particular
interest are epigenetic processes that regulate gene expres-
sion via modifications to DNA, histone proteins, and
chromatin. DNA methylation is the best-characterized
epigenetic modification, stably influencing gene expres-
sion via disruption of transcription factor binding and
recruitment of methyl-binding proteins that initiate chro-
matin compaction and gene silencing. Despite being trad-
itionally regarded as a mechanism of transcriptional
repression, DNA methylation is actually associated with
both increased and decreased gene expression [6], and
other genomic functions including alternative splicing and
promoter usage [7]. The availability of high-throughput
profiling methods for quantifying DNA methylation across
the genome at single-base resolution in large numbers of
samples has enabled researchers to perform epigenome-
wide association studies (EWAS) aimed at identifying
methylomic variation associated with environmental ex-
posure and disease [8]; however, these studies are
inherently more complex to design and interpret than
GWAS [9–11]. The dynamic nature of epigenetic pro-
cesses means that unlike in genetic epidemiology a range
of potentially important confounding factors need to be
considered, including tissue or cell type, age, sex, lifestyle
exposures, and reverse causation [9]. In recent years there
has been a growing interest in the role of developmentally
regulated epigenetic variation in the molecular etiology of
schizophrenia, supported by data from recent analyses of
DNA methylation in co-twins from disease-discordant
monozygotic twin pairs [12], clinical sample cohorts [13,
14], and post-mortem brain tissue [15–17].
A better understanding of the molecular mechanisms
underlying disease phenotypes is best achieved using an
integrated functional genomics strategy, although few
studies have attempted to systematically integrate genetic
and epigenetic epidemiological approaches. For example,
we previously demonstrated how DNA methylation is
under local genetic control, identifying an enrichment of
DNA methylation quantitative trait loci (mQTL) amongst
genomic regions associated with schizophrenia, and
highlighting how mQTLs can be used to refine GWAS
loci by identifying discrete sites of regulatory vari-
ation associated with schizophrenia risk variants [18].
There is also potential for using polygenic risk scores
(PRS) – defined as the sum of trait-associated alleles
across many genetic loci, weighted by effect sizes es-
timated by GWAS analyses – as disease biomarkers,
although their utility for exploring the molecular gen-
omic mechanisms involved in disease pathogenesis is
largely unexplored. For example, PRS-associated epigen-
etic variation is potentially less affected by factors associ-
ated with the disease itself (e.g., medication exposure,
stress, and smoking), which can confound case–control
analyses.
In this study we present a methodological framework
for large EWAS and report widespread differences in
DNA methylation between schizophrenia patients and
controls in the largest analysis yet undertaken. Lever-
aging on previous investments in GWAS analyses in
schizophrenia, we assessed genome-wide patterns of
DNA methylation in a total of 1714 individuals from
three independent sample cohorts to identify molecular
biomarkers of the disease. Using genetic data from the
same individuals, we performed an integrated genetic-
epigenetic study to further our functional understanding
of common variants associated with schizophrenia eti-
ology. We demonstrate the utility of using PRS for
identifying molecular variation associated with etio-
logical variation, and mQTLs for refining the functional/
regulatory variation associated with schizophrenia risk
variants. Finally, we present strong evidence for the co-
localization of genetic associations for schizophrenia and
differential DNA methylation.
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Results and discussion
Methodological overview
We performed a multi-stage EWAS of (1) schizophrenia
and (2) schizophrenia PRS, quantifying genome-wide pat-
terns of DNA methylation using the Illumina Infinium
HumanMethylation450 BeadChip (“450 K array”) (Illu-
mina Inc., San Diego, CA, USA) in DNA samples isolated
from whole blood. After implementing a stringent quality
control pipeline (see Methods), our “discovery cohort”
(phase 1) included 675 individuals (353 schizophrenia
cases and 322 non-psychiatric controls). Schizophrenia-
associated differentially methylated positions (DMPs) were
subsequently tested in an independent “replication cohort”
(phase 2) of 847 individuals (414 schizophrenia cases
and 433 non-psychiatric controls; phase 2) and 96
monozygotic (MZ) twin pairs (phase 3). We tested for
a significant enrichment of schizophrenia-associated
DMPs in regulatory regions, gene ontology (GO)
pathways, and genomic regions identified in the re-
cent PGC GWAS of schizophrenia [2]. Finally, we inte-
grated our genetic and epigenetic data to interrogate
mQTLs across robust schizophrenia-associated GWAS re-
gions, utilizing Bayesian co-localization analyses to identify
genetic variants associated with both schizophrenia and
methylomic variation. An overview of our methodological
approach is presented in Additional file 1: Figure S1.
Controlling for confounders in epigenetic epidemiology:
smoking as an important covariate for schizophrenia EWAS
Our initial analysis of the phase 1 cohort included covar-
iates for sex and experimental batch, in addition to age
and cell composition measures derived from the DNA
methylation data [19–21]. We identified 160 schizophrenia-
associated DMPs at a stringent experiment-wide sig-
nificance threshold (P < 1 × 10−7) representing a 5 %
family-wise error-rate estimated from 5000 permutations
(see Methods). The top-ranked DMPs were annotated to
AHRR (cg05575921, cg21161138, cg26529655, cg25648
203), F2RL3 (cg03636183), GFI1 (cg09935388), and
MYO1G (cg12803068, cg22132788), in addition to inter-
genic regions on chromosome 6p21.33 (cg06126421,
cg14753356) and 2q37.1 (cg01940273, cg05951221)
(Additional file 2: Table S1). Altered DNA methylation at
each of these DMPs has been previously associated with
cigarette smoking [22–24] (Fig. 1), consistent with epi-
demiological data highlighting elevated smoking rates and
intensity in patients with schizophrenia [25–27]. Because
detailed smoking information was not available for every
individual in the phase 1 cohort, we derived a proxy vari-
able using DNA methylation values for sites on the 450 K
array previously associated with smoking [22, 23]. The
resulting smoking scores were consistent with actual
smoking status for samples with available smoking data,
with current smokers having higher scores than non-
smokers (Additional file 1: Figure S2). Across the full sam-
ple, DNA methylation-derived smoking scores were sig-
nificantly higher in patients with schizophrenia compared
to controls (Mann–Whitney P = 1.51 × 10−41; Additional
file 1: Figure S3), consistent with epidemiological data
[25–27] and the results of our initial EWAS. We next
repeated our schizophrenia EWAS analysis using these
derived smoking scores as covariates; smoking-associated
probes (P < 1 × 10−7 in [22]) were no longer differentially
methylated in the patients with schizophrenia (P > 1 × 10−7;
Additional file 1: Figure S4 and Additional file 2: Table S2)
with the exception of cg05575921 (annotated to AHRR; P =
1.62 × 10−14). Although it is possible that DNA methylation
at this locus is associated with schizophrenia beyond the
confounding effects of smoking, we took the final step of
removing all smoking-associated probes from subsequent
analyses to enable a clear interpretation of our data.
DMPs associated with schizophrenia are robust to
additional confounding
In total we identified 25 DMPs associated with schizo-
phrenia passing our stringent experiment-wide signifi-
cance threshold (P < 1 × 10−7) when controlling for age,
sex, experimental batch, and derived estimates of cell
composition and smoking (Table 1, Additional file 1:
Figure S5). An additional 1223 DMPs were identified
at a more relaxed “discovery” threshold of P < 5 × 10−5
(Additional file 2: Table S3). Because it is likely that
other unmeasured environmental exposures also con-
found our case–control analysis of methylomic variation
associated with schizophrenia, we investigated the impact
of additional surrogate variables capturing variation in
DNA methylation on the association statistics for
schizophrenia-associated DMPs. We first compared each
of the first 10 principal components (PCs) derived from
the DNA methylation data to the available phenotype data
to identify potential sources of additional variation be-
tween samples (Additional file 1: Figure S6). For example,
we observed strong correlations (r > 0.5) between the first
three PCs and estimated blood cell composition measures,
reflecting the likely effect of epigenetic differences be-
tween cell types. Age was moderately correlated (r > 0.2)
with PCs 3, 8, and 9; sex was moderately correlated
(r > 0.2) with PCs 6 and 7; and smoking was weakly
correlated (r < 0.2) with each of the top 10 PCs. Although
PCs are routinely included in GWAS analyses to control
for population stratification, they have not been widely
used in DNA methylation studies. We compared the re-
gression coefficients from our initial analysis model (con-
trolling for age, sex, batch, cell composition, and derived
smoking score) to sequential models iteratively including
up to 10 PCs. We observed a strong positive correlation
for schizophrenia-associated DNA methylation differences
between analyses (Spearman’s r = 0.629 to 0.820), with
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even stronger similarities observed for the top 1223 dis-
covery schizophrenia-associated DMPs (Spearman’s r =
0.952 to 0.983) (Additional file 1: Figure S7). Although
additional (unmeasured) confounders are likely to exist in
our dataset (e.g., medication exposures, drugs of abuse
and stress), our sensitivity analyses showed that the identi-
fied schizophrenia-associated DMPs were relatively robust
to the major PCs associated with methylomic variance in
this dataset.
Evidence of coordinated differential DNA methylation
associated with schizophrenia across genomic regions
We next sought to identify extended regions charac-
terized by schizophrenia-associated DNA methylation
differences spanning multiple Illumina 450 K probes,
implementing two methodological approaches to define
differentially methylated regions (DMRs). First, we
employed the comb-p algorithm that corrects the DMP
P values for auto-correlation between probes and then
scans the genome for peaks of association around a seed
signal (set to P < 5 × 10−5) [28]. For each region it cal-
culates the Stouffer–Liptak corrected P value, which
is then adjusted for multiple testing using Šidák’s
correction. This approach identified 12 significant
schizophrenia-associated DMRs (Šidák-corrected P < 0.05)
spanning between 2 and 20 DNA methylation sites
(Additional file 2: Table S4). The top-ranked DMR identi-
fied using this approach spanned 20 CpG sites overlapping
the major histocompatibility complex (MHC) on chromo-
some 6, noteworthy as it is the most robustly associated
locus in schizophrenia GWAS [2, 29–32]. Second, in
order to identify groups of sites that may not contain
highly significant individual DMPs but are instead charac-
terized by an extended region of contiguous differential
DNA methylation associated with schizophrenia, we used
a sliding window approach (see Methods) [33], using
permutations to establish an appropriate multiple testing
threshold (set at P < 3 × 10−7 for 5 % family-wise error).
We identified 531 schizophrenia-associated regions, which
were filtered to a set of 76 non-overlapping regions
(Additional file 2: Table S5). Three of the 12 DMRs
identified by comb-p were also identified as DMRs
using this sliding window approach. The 76 DMRs
contained between 2 and 120 probes (median 8.5),
Fig. 1 It is critical to control for smoking in an epigenome-wide association study (EWAS) of schizophrenia. Manhattan plots comparing association
P-values (y-axis, −log10 scale) against genomic location (x-axis) for (a) an EWAS of schizophrenia case–control status without inclusion of a smoking
covariate, (b) a published EWAS of tobacco smoking (never versus current) [22], and (c) an EWAS of schizophrenia case–control status including a DNA
methylation-derived smoking score as a covariate. There is considerable overlap between the associated loci in panels a and b (e.g., on chromosomes
2, 5, 6, and 19), implying that the elevated rate and intensity of smoking in patients with schizophrenia [25–27] is a severe confounder in this analysis.
In contrast, there is no overlap in the associated loci shown in panels b and c, suggesting that the derived smoking score effectively removes these
false positives
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with the DMR P value not biased by the number of
probes within each region (Additional file 1: Figure
S8). Of note, 30 (36 %) of these genomic regions were
not implicated by the probe-wise analysis, and for the
majority (96 %) of regions, the DMR P values were
more significant than the best individual probe P value,
suggesting that there might be multiple semi-independent
DMPs in these regions (Additional file 1: Figure S9). The
top DMR (P = 1.87 × 10−14) identified using this approach
spanned three probes within GYG1 on chromosome 3
(Additional file 1: Figure S10), a gene previously shown to
be differentially expressed in prefrontal pyramidal neurons
from patients with schizophrenia [34].
Schizophrenia-associated DMPs are enriched in
transcription factor binding sites and in the vicinity of
genes involved in immune-related pathways
We investigated whether the 1223 phase 1 discovery
DMPs (P < 5 × 10−5) are enriched in specific regulatory
domains identified in the ENCODE project [35, 36]. We
found no significant enrichment of DMPs within DNAse
I hypersensitivity sites (DHS) (Additional file 2: Table S6;
P > 0.05) and a significant depletion of DMPs in the
broad set of transcription factor binding sites [odds ratio
(OR) = 0.852, P = 0.00542]. We identified a significant
enrichment (P < 0.00338; corrected for 148 transcription
factors) in certain specific transcription factor binding
motifs including BATF (OR = 4.90, P = 5.04 × 10−16),
BCL11A (OR = 3.48, P = 2.08 × 10−7), IRF4 (M-17) (OR =
2.20, P = 1.71 × 10−5), and MEF2A (OR = 2.13, P = 3.04 ×
10−5), and a significant depletion in HA-E2F1 binding-
sites (OR = 0.701, P = 0.000319). In order to investigate
functional relationships between the 955 genes annotated
to the 1223 phase 1 discovery DMPs, we tested for an
over-representation of ontological categories and path-
ways using a method that controls for the number of
probes annotated to each gene on the 450 K array (see
Methods). Given the hierarchical structure of the
Table 1 Schizophrenia-associated differentially methylated positions
Probe ID DNA methylation difference (%) P value Chromosome Base position Gene annotation
cg10311104 0.80 9.75E−10 7 23053899 FAM126A TSS200
cg08752433 2.78 1.05E−09 12 111016566 PPTC7 Body
cg26314722 1.85 1.73E−09 1 234867300
cg24054898 1.64 5.91E−09 3 148721868 GYG1 Body
cg23684410 2.40 6.13E−09 11 116897558 SIK3 Body
cg00945209 1.91 9.66E−09 17 76801579 USP36 Body
cg18518074 2.29 1.03E−08 11 64642316 EHD1 Body
cg09706133 1.23 1.31E−08 15 68659758 ITGA11 Body
cg21522988 2.06 1.80E−08 12 29376872 FAR2 5′UTR
cg02656560 1.69 3.14E−08 17 19967600
cg11418177 2.03 3.50E−08 4 142636072 IL15 5′UTR
cg06736148 2.14 3.68E−08 15 52416833 GNB5 Body
cg08655071 1.74 4.74E−08 1 209928895 TRAF3IP3 TSS1500
cg00829438 −1.02 5.26E−08 9 136213035 MED22 Body
cg27541604 1.65 5.57E−08 1 159046451 AIM2 5′UTR;1stExon
cg03149593 −1.24 5.98E−08 3 136988095
cg14178364 1.44 6.43E−08 9 37529128 FBXO10 Body
cg14038731 1.42 6.70E−08 6 110732536 DDO Body
cg20737259 −3.09 7.79E−08 4 95038723
cg09470958 1.20 8.35E−08 6 31055471
cg13803727 1.43 8.65E−08 9 89445247
cg03402926 1.72 8.77E−08 11 27340767
cg07326387 −2.10 9.16E−08 4 44543613
cg00092992 1.80 9.69E−08 1 33596100
cg03665078 1.58 9.98E−08 5 118689961 TNFAIP8 Body
Listed are all differentially methylated positions (DMPs) associated with schizophrenia (P < 1 × 10−7) with the corresponding P values and regression coefficients
from the phase 1 discovery cohort. All DMPs with P < 5 × 10−5 are listed in Additional file 2: Table S3 with the corresponding P values and regression coefficients
for the two independent replication cohorts
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ontological annotations, many of the significant terms are
not independent and are associated by virtue of their over-
lapping membership; we therefore sought to group terms
where the significant enrichment was explained by the
overlap with a more significant term (see Methods), iden-
tifying 153 groups of related GO categories (Additional
file 2: Table S7). The top-ranked group of pathways were
related to immune function, consistent with findings from
genetic [37], transcriptomic [38, 39], and epidemiological
data [40, 41]. The second-ranked group of pathways were
related to neuronal proliferation and brain development,
an interesting observation given the hypothesized neuro-
developmental origins of schizophrenia [42].
Replication of schizophrenia-associated DMPs in two
independent cohorts
We next sought to confirm the identified schizophrenia-
associated differences in an independent replication
sample (phase 2) by generating 450 K array data from an
additional 414 patients with schizophrenia and 433 non-
psychiatric controls. As with the phase 1 cohort, patients
with schizophrenia were characterized by a significantly
higher smoking score derived from Illumina 450 K array
DNA methylation data (Mann–Whitney P = 1.15 × 10−22;
Additional file 1: Figure S3). We therefore employed an
analysis model controlling for age, sex, batch, cell compos-
ition, and smoking to identify schizophrenia-associated
differences at nominated DMPs. The 25 experiment-wide
significant (P < 1 × 10−7) DMPs identified in phase 1
were characterized by highly consistent schizophrenia-
associated differences in the same direction in the
phase 2 dataset (sign test P = 7.75 × 10−7) (Fig. 2a); 14
of these DMPs were characterized by experiment-wide
significant (P < 1 × 10-7) differences in the same direc-
tion in phase 2, with five additional DMPs significant
at P < 5 × 10−5. The phase 1 discovery DMPs (P < 5 ×
10−5) were also characterized by highly consistent
schizophrenia-associated differences in phase 2, with
1159 (94.8 %) having a consistent direction of effect
(sign test P = 4.25 × 10−261). Of the phase 1 DMPs,
137 (11.2 %), 249 (20.4 %), and 245 (20.0 %) were as-
sociated at P < 1 × 10−7, P < 5 × 10−5, and P < 4.09 × 10−5
(correcting for 1223 DMPs) respectively (Additional file 2:
Table S3).
We next tested the schizophrenia-associated DMPs
from phase 1 in a sample of 96 monozygotic twin pairs
(phase 3); the analysis of MZ twins is a powerful tool in
epigenetic epidemiology, as they do not differ for many
of the confounders that can influence case–control
analyses (e.g., age, sex, genotype) [9]. Although none of
the top-ranked phase 1 DMPs (P < 1 × 10−7) reached
experiment-wide significance in the twin dataset (mini-
mum P = 1.11 × 10−4; Additional file 2: Table S3), this is
not surprising given the relatively small number of twin
pairs, and schizophrenia-associated differences were
highly correlated with those identified in phase 1. Strik-
ingly, 24 out of 25 (96 %) experiment-wide significant
DMPs (sign test P = 7.75 × 10−7) and 1113 out of 1216
(91.5 %) phase 1 discovery DMPs (Fig. 2b; sign test P =
6.47 × 10−215) were characterized by schizophrenia-
associated differences in the same direction, demonstrat-
ing that these effects were not confounded by factors
such as genotype and sex that are perfectly matched be-
tween genetically identical twins. Finally, a meta-analysis
across the three independent datasets demonstrated that
22 out of 25 (88 %) of the phase 1 experiment-wide sig-
nificant DMPs were characterized by an experiment-
wide significant association across all cohorts, with an
additional 343 experiment-wide DMPs (P < 1 × 10−7)
identified in the combined meta-analysis (Fig. 2c,
Additional file 1: Figure S11, Additional file 2: Table S8,
and Additional file 3).
Differential DNA methylation associated with polygenic
burden for schizophrenia
Many common DNA sequence variants, each conferring a
small effect on susceptibility, mediate risk for schizophre-
nia [2, 29, 30, 43]. Beyond the specific genome-wide
significant loci identified in GWAS, an individual’s accu-
mulated genetic burden can be quantified to define an
overall PRS – that is, the sum of trait-associated alleles
across many genetic loci, weighted by effect sizes esti-
mated by GWAS analyses [43]. It has been suggested that
an individual’s PRS may function as a less confounded
phenotype for molecular epidemiology, quantitatively
indexing underlying neurobiological phenotypes associ-
ated with susceptibility. Schizophrenia PRSs were calcu-
lated for 639 samples in the phase 1 cohort based on
genetic association data from the recent large PGC
GWAS analysis of schizophrenia [2] (see Methods). As
expected, patients with schizophrenia had a significantly
higher PRS than control samples (P = 3.34 × 10−27;
Additional file 1: Figure S12), confirming a higher poly-
genic burden of common risk variants in this group. We
next performed an EWAS of the schizophrenia PRS, using
a linear model controlling for the covariates of age, sex,
and cell counts derived from the DNA methylation data,
but not smoking status (see Methods). Unlike the analysis
of schizophrenia diagnosis, we did not see an enrichment
of smoking-associated DMPs (Additional file 1: Figures
S13 and S14), indicating that increased smoking rates in
schizophrenia might not result from the underlying
common polygenic architecture of the disease. Performing
a sensitivity analysis using PCs derived from the DNA
methylation data iteratively (as described above)
highlighted similar strong correlations (r = 0.963–0.980)
with the effects identified in the initial EWAS (Additional
file 1: Figure S15). Two DMPs were associated with
Hannon et al. Genome Biology  (2016) 17:176 Page 6 of 16
schizophrenia PRS at our experiment-wide significance
threshold (P < 1 × 10–7), with 156 DMPs identified at
the more relaxed discovery threshold of P < 5 × 10−5
(Additional file 2: Table S9). Of note, the top-ranked
disease- and PRS-associated DMPs are distinct, with
no site reaching experiment-wide significance in both
analyses (Fig. 3). Given our previous finding that
there is an enrichment of mQTLs amongst SNPs as-
sociated with schizophrenia [18], we investigated
whether any of the PRS-associated DMPs resulted dir-
ectly from such genetic associations. Performing an
mQTL analysis for all genetic variants incorporated in
the PRS, we identified no overlap with DNA methyla-
tion sites associated with PRS. We next investigated
PRS-associated DMPs in samples from our phase 2
replication cohort for whom genotype data were available
(n = 843), in which patients with schizophrenia were again
characterized by a significantly higher schizophrenia PRS
than controls (P = 2.09 × 10−31; Additional file 1: Figure
S12). Although none of the 156 DMPs reached
experiment-wide significance in the phase 2 dataset
(minimum P = 0.000121; Additional file 2: Table S9),
effect sizes were again strongly correlated and there
was a significant excess of consistent changes across
both cohorts (123/156 sign test P = 1.05 × 10−13; Additional
file 1: Figure S16).
Differentially methylated sites overlap schizophrenia
GWAS loci
We next examined whether there is any overlap between
the location of DMPs identified in this study and the
105 autosomal genomic regions nominated by the recent
GWAS of schizophrenia [2]. These regions were derived
by the PGC by “clumping” the GWAS P values so that
multiple non-independent associations were collapsed
into a single associated loci. Briefly, we generated a com-
bined differential methylation P value from the individual
probes, taking into account the correlation structure be-
tween them [33] (see Methods); 76 of the GWAS regions
contained more than one 450 K array probe (median = 35,
range = 2–504) and were appropriate for generating a
combined P value. From these, we identified 27 regions
Fig. 2 Replication of schizophrenia-associated DNA methylation differences identified in the phase 1 analysis in two independent cohorts. Shown
are scatterplots demonstrating the concordance in effect size [schizophrenia-associated DNA methylation difference (%)] between the phase 1
(case–control) cohort (n = 675) (x-axis) and either the (a) phase 2 (case–control) cohort (n = 847) or (b) phase 3 (n = 96 monozygotic twin pairs)
cohort for probes associated with schizophrenia at both the experiment-wide (P < 1 × 10−7; red circles) and discovery (P < 5 × 10−5; blue triangles)
P-value thresholds. Many of these individual DNA methylation sites are significantly associated with schizophrenia in the replication cohorts
(Table 1 and Additional file 2: Table S3). Meta-analyses across the three independent cohorts identified many additional sites significantly associated
with schizophrenia at P < 1 × 10−7. (c) A forest plot of the top ranked probe from the meta-analysis (cg02488934), with the effect size and standard
error (SE) from each individual cohort and the pooled effect from the meta-analysis. CI confidence interval
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(35.5 %) that demonstrated significant differences in DNA
methylation (Bonferroni corrected threshold P < 0.000658;
Additional file 2: Table S10) in schizophrenia samples
compared to controls, of which nine were also character-
ized by a significant combined PRS EWAS P value. The
top region is plotted in Fig. 4, highlighting multiple sites
of differential DNA methylation across the whole LD
block. Because these regions were larger than those con-
sidered for the sliding window approach, we generated
empirical P values (see Methods) to confirm significant as-
sociations across 25 of the 27 schizophrenia-associated re-
gions and four of nine PRS-associated regions. In all of
these DMRs, the combined P value was more significant
than the best DMP P value (Additional file 1: Figure S17),
suggesting that there might be multiple semi-
independently associated differentially methylated
sites across these regions. Taken together, these re-
sults support previous findings that schizophrenia-
associated DNA methylation differences overlap with
genetic susceptibility loci [44, 45].
Evidence that schizophrenia GWAS signals co-localize
with mQTLs
Although an enrichment of schizophrenia-associated
DMPs in regions identified in GWAS is consistent with
DNA methylation mediating the relationship between
common risk variants and pathogenesis, this association
does not establish a direct causal link. Motivated by this,
we performed a Bayesian co-localization analysis [46] in
phase 1 samples for which both genetic and DNA
methylation data were available (n = 639). Briefly, this
approach compares the pattern of association results
from two independent GWAS (i.e. of schizophrenia and
DNA methylation) to see if they are indexing an associ-
ation with the same causal variant. We considered
mQTL data for 23,649 unique Illumina 450 K probes
located within 500 kb of the 105 autosomal GWAS-
nominated regions defined by the PGC [2]. Because
some probes were located in more than one GWAS
region, we assessed a total of 23,918 potential mQTL
pairs with schizophrenia. The posterior probabilities for
80 regions, involving DNA methylation sites in 1375
mQTL pairs, are supportive of a co-localized association
signal for both schizophrenia and DNA methylation in
that region (PP3 + PP4 > 0.99; Additional file 2: Table S11).
Of these pairs, 127 (covering 39 regions associated with
schizophrenia) had a higher posterior probability for both
schizophrenia and DNA methylation, being associated
with the same causal variant (PP4/PP3 > 1), with 66
(over 27 regions) of these having sufficient support
for them to be considered as “convincing” (PP4/PP3 > 5)
according to the criteria of Guo and colleagues [47]. We
Fig. 3 There is minimal overlap between significant schizophrenia-associated differentially methylated positions and those associated with the
schizophrenia polygenic risk score (PRS). Shown is a scatterplot comparing probe-wise significance in the epigenome-wide association study
(EWAS) of schizophrenia case status (x-axis) and PRS (y-axis). Data are presented for probes identified as significant (P < 5 × 10−5) in the schizophrenia
EWAS (red circles), PRS EWAS (blue triangles), or both (green diamonds)
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next compared these results to a similar analysis per-
formed in a smaller sample of post-mortem brains [18].
Of 16 convincing pairs identified in brain, nine also had
evidence of a co-localized association signal (PP3 + PP4 >
0.99) for both schizophrenia and DNA methylation in
blood, seven (44 %) of which were also classed as demon-
strating convincing co-localization with blood mQTLs
(Table 2). One such example of this is shown in Fig. 5,
highlighting a similar profile of GWAS P values across the
region for schizophrenia and the mQTL in both
blood and brain (additional examples are presented in
Additional file 4).
Conclusions
This study is the first systematic integrated analysis of
genetic and epigenetic variation in schizophrenia, intro-
ducing a methodological pipeline that can be used to
inform EWAS analyses of other traits and diseases. We
have identified multiple DMPs and DMRs associated
with schizophrenia, independently of important con-
founders such as smoking, with striking levels of replica-
tion in independent sample cohorts. We also show that
polygenic burden for schizophrenia is associated with
epigenetic variation across the genome, independently of
loci implicated in the analysis of diagnosed schizophrenia.
Finally, we have used mQTL analyses to annotate the
extended genomic regions nominated by GWAS analyses
of schizophrenia, using co-localization analyses to high-
light potential regulatory variation causally involved in
disease.
Methods
All experimental methods were in accordance with the
Helsinki declaration.
Cohort description: phase 1- University College London
The University College London case–control sample has
been described elsewhere [48] but briefly comprises
of unrelated ancestrally matched cases and controls from
the UK. Case participants were recruited from UK Na-
tional Health Service (NHS) mental health services with
a clinical International Classification of Diseases 10th
edition (ICD-10) diagnosis of schizophrenia. All case
participants were interviewed with the Schedule for
Affective Disorders and Schizophrenia-Lifetime Version
(SADS-L) [49] to confirm Research Diagnostic Criteria
(RDC) diagnosis. A control sample screened for an ab-
sence of mental health problems was recruited. Each
control subject was interviewed to confirm that they did
not have a personal history of an RDC-defined mental
Fig. 4 Evidence for schizophrenia-associated differential DNA methylation within genome-wide association study (GWAS)-nominated genomic
regions. A Manhattan plot of an example genomic region (chr10:104423800-105165583) identified in the recent GWAS of schizophrenia [2]
illustrates the location (x-axis) of genetic variants and Illumina 450 K probes against their significance with schizophrenia (y-axis; −log10 P value).
Gene locations (exons and introns) are depicted above the Manhattan plot. Red diamonds depict GWAS results, green circles depict results from
our phase 1 schizophrenia EWAS, and blue triangles depict results from our schizophrenia polygenic risk score EWAS
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Table 2 Convincing co-localization of schizophrenia and DNA methylation genome-wide association study signals in blood and
brain
Schizophrenia
GWAS region
Probe ID Chr Base position Gene annotation Bayesian co-localization
mQTL in blood mQTL in brain
nsnps PP3 + PP4 PP4/PP3 nsnps PP3 + PP4 PP4/PP3
108 cg00585072 5 140186983 PCDHA2;PCDHA1;
PCDHA4;PCDHA3
1595 0.9982 5.340 1260 0.9983 6.058
7 cg02951883 7 2050386 MAD1L1 1808 1.0000 14.596 2144 0.9992 11.820
3 cg08772003 10 104629869 AS3MT 1994 1.0000 51.075 1316 1.0000 36.981
3 cg11784071 10 104629166 AS3MT 1994 0.9999 8.046 1315 1.0000 39.298
3 cg24592962 10 104629151 AS3MT 1994 0.9986 36.510 1315 1.0000 55.055
99 cg14258853 12 29935411 TMTC1 3551 0.9995 46.932 2598 0.9989 10.723
47 cg26732615 19 19648335 CILP2;YJEFN3 1644 1.0000 8.196 1285 0.9906 5.514
Listed are all instances where the GWAS results indicate that the same causal variant is associated with schizophrenia and DNA methylation at a specific site in
both blood and brain. Bayesian co-localization analysis compared the GWAS results evaluating the evidence for five hypotheses (see Methods); convincing
co-localization signs were defined as PP3 + PP4 > 0.99 and PP4/PP3 > 5. The full set of results for all genetic loci associated with schizophrenia can be found in
Additional file 2: Table S12.
Chr chromosome, GWAS genome-wide association study; mQTL DNA methylation quantitative trait loci; nsnps number of SNPs
Fig. 5 Co-localization of genome-wide association study (GWAS) signals associated with both schizophrenia and DNA methylation in blood and
brain. Manhattan plots illustrate the location of genetic variants (x-axis) and their significance (y-axis; −log10 scale) in GWAS of schizophrenia (a),
and DNA methylation at cg24592962 in blood (b) and brain (c). The solid red line indicates the location of the DNA methylation site (cg24592962).
Comparing the pattern of these results for the mQTL and schizophrenia is supportive of the same causal variant being associated with both.
Other examples are presented in Additional file 4
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disorder or a family history of schizophrenia, bipolar dis-
order, or alcohol dependence. UK NHS multicenter and
local research ethics approval was obtained and all par-
ticipants signed an approved consent form after reading
an information sheet.
Cohort description: phase 2 – Aberdeen
The Aberdeen case–control sample has been described
elsewhere [50] but briefly contains patients with schizo-
phrenia and controls who have self-identified as born in
the British Isles (95 % in Scotland). All cases met the
Diagnostic and Statistical Manual for Mental Disorders
fourth edition (DSM-IV) and ICD-10 criteria for schizo-
phrenia. Diagnosis was made by Operational Criteria
Checklist (OPCRIT). All case participants were
outpatients or stable inpatients. Detailed medical and
psychiatric histories were collected. A clinical interview
using the Structured Clinical Interview for DSM-IV
(SCID) was also performed on schizophrenia cases. Con-
trols were volunteers recruited through general practices
in Scotland. Practice lists were screened for potentially
suitable volunteers by age and sex and by exclusion of
individuals with major mental illness or use of neuro-
leptic medication. Volunteers who replied to a written
invitation were interviewed using a short questionnaire
to exclude major mental illness in the individual them-
selves and their first-degree relatives. All cases and con-
trols gave informed consent. The study was approved by
both local and multiregional academic ethical committees.
Cohort description: phase 3 – monozygotic twins
The MZ twin cohort is a multi-center collaborative pro-
ject aimed at identifying DNA methylation differences in
MZ twin pairs discordant for schizophrenia. We identi-
fied 96 informative twin-pairs (n = 192 individuals) from
European twin studies based in Utrecht (The Netherlands),
Helsinki (Finland), London (UK), Stockholm (Sweden),
and Jena (Germany). Of the MZ twin pairs utilized in the
analysis, 75 were discordant for diagnosed schizophrenia,
six were concordant for schizophrenia, and 15 twin pairs
were free of any psychiatric disease. In this analysis we
tested specific DNA methylation probes nominated from
our case–control analysis; a more detailed description of
the cohort along with more in-depth analysis is currently
under preparation (Dempster et al., in preparation).
Genome-wide quantification of DNA methylation
The EZ-96 DNA Methylation kit (Zymo Research, CA,
USA) was used to treat 500 ng of DNA from each sam-
ple with sodium bisulfite in duplicate. DNA methylation
was quantified using the Illumina Infinium Human-
Methylation450 BeadChip (Illumina Inc.) run on an Illu-
mina iScan System (Illumina) using the manufacturers’
standard protocol. Samples were randomly assigned to
chips and plates to ensure equal distribution of cases
and controls across arrays and to minimize batch effects.
In addition, a fully methylated control (CpG Methylated
HeLa Genomic DNA; New England BioLabs, MA, USA)
was included in a random position on each plate.
Signal intensities were imported in the R programming
environment using the methylumIDAT() function in the
methylumi package [51]. Our stringent quality control
pipeline included the following steps: (1) checking meth-
ylated and unmethylated signal intensities, excluding
samples where this was <2500; (2) using the 10 control
probes to ensure the bisulfite conversion was successful,
excluding any samples with median <90; (3) identifying
the fully methylated control sample was in the correct
location; (4) all tissues predicted as of blood origin using
the tissue prediction from the Epigenetic Clock software
(https://dnamage.genetics.ucla.edu/) [21]; (5) multidi-
mensional scaling of sites on X and Y chromosomes
separately to confirm reported gender; (6) comparison of
genotype data for up to 65 single nucleotide polymorphism
(SNP) probes on 450 K array; and (7) use of the pfilter()
function from wateRmelon package [52] to exclude sam-
ples with >1 % of probes with detection P value > 0.05 and
probes with >1 % of samples with detection P value > 0.05.
PCs were used (calculated across all probes) to identify
outliers, samples >2 standard deviations from the mean for
both PC1 and PC2 were removed. Finally, we checked the
correlation (r = 0.927) of reported age with that predicted
by the Epigenetic Clock. Normalization of the DNA
methylation data was performed used the dasen() function
in the wateRmelon package [52]. Due to a different experi-
mental design, the phase 3 cohort was performed so that
both members of each MZ twin pair were run on the same
chip. Data processing followed a similar pipeline with an
additional step using the 65 SNP probes to confirm that
twins were genetically identical.
Genotyping
Genotyping was performed using the Affymetrix Map-
ping 500 K Array and the Genomewide Human SNP
Array 5.0 or 6.0 (Affymetrix, CA, USA). Genotypes were
called from raw intensity data using the Birdseed com-
ponent of the Birdsuite algorithm [53, 54]. Samples were
genotyped by the Genetic Analysis Platform at The
Broad Institute of Harvard and MIT according to stand-
ard protocols.
Imputation
Prior to imputation, PLINK [55] was used to remove
samples with >5 % missing data. We also excluded SNPs
characterized by >5 % missing values, a Hardy–Weinberg
equilibrium P value < 0.001 and a minor allele fre-
quency of <5 %. Imputation was performed using
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ChunkChromosome (http://genome.sph.umich.edu/wiki/
ChunkChromosome) and Minimac2 [56, 57] with the
1000 Genomes reference panel of European samples
(phase 1, version 3). Imputed genotypes were then con-
verted back in the PLINK format files using fcgene [58]
only including variants with Rsq > 0.3. SNPs were then
refiltered with PLINK such that they satified the cri-
teria: <1 % missing values, Hardy–Weinburg equilibrium
P-value < 0.001, and a minor allele frequency of >5 %. Sub-
sequently, SNPs were also filtered so that each of the three
genotype groups with zero, one, or two minor alleles (or
two genotype groups in the case of rare SNPs with zero or
one minor allele) had a minimum of five observations.
DNA methylation smoking score
As smoking status information was not present for all
samples, we estimated a proxy based on the DNA
methylation profile at sites known to be associated with
smoking status following the approach in [22]. This
methodology produces a weighted score across 183 DNA
methylation sites, where the weights were taken from the
smoking EWAS in [23].
Polygenic risk scores
As samples from both phase 1 and phase 2 were in-
cluded in the PGC GWAS of schizophrenia, we obtained
the PRS scores from these analyses calculated as part of
the leave one out validation experiment, where the train-
ing dataset (to derive weights for associated scores) was
based on all samples bar one source dataset in which the
PRSs were calculated [2]. In this analysis we used the
scores calculated across an independent set of variants
with P value < 0.05.
Statistical analysis
Probes previously identified as containing a common
SNP (allele frequency > 5 % in European populations)
within 10 base pairs (bp) of the single base extension
position [59] or potentially cross-hybridizing to multiple
genomic locations [59, 60] were removed prior to analysis.
A linear regression model was used to test for differen-
tially methylated sites associated with schizophrenia. DNA
methylation values for each probe were regressed against
case–control status with covariates for age, gender, and
cell composition. As cell count data were not available for
these DNA samples, these were estimated from the DNA
methylation data using both the Epigenetic Clock software
[21] and Houseman algorithm [19, 20], including the
seven variables recommended in the documentation for
the Epigenetic Clock in the regression analysis. Additional
regression models including smoking score and principal
components, also derived from DNA methylation, were
also performed. For the twins a linear model was used to
generate regression coefficients, but clustered standard
errors using the plm package [61] – recognizing individ-
uals from the same twin pair – were used to calculate P-
values. DMP results are annotated with their genomic lo-
cation and gene annotation taken from the annotation
files provided by Illumina. In addition, transcription factor
binding site and DHS site annotation were taken from the
supplementary files provided by Slieker and colleagues
[36].
Multiple testing threshold
To establish the multiple testing significance threshold,
5000 permutations were performed repeating the linear
regression model for randomly selected groups of cases
and controls to match the numbers in the phase 1 data.
For each permutation, P values from the EWAS were
saved and the minimum identified. Across all permuta-
tions the fifth percentile was calculated to generate the
5 % alpha significance threshold.
Regional analysis
Two different region approaches were used. First, the
results for every probe were converted into a BED file
(containing genomic location and EWAS P value) and
run through the comb-p [28] pipeline with a seed of 5 ×
10−5 and distance parameter set to 500 bp. Briefly,
comb-p generates DMRs by (1) calculating the auto-
correlation between probes to adjust the input DMP P-
values using the Stouffer–Liptak–Kechris correction, (2)
running a peak finding algorithm over these adjusted
P values to identify enriched regions around a seed
signal, (3) calculating the region P value using the Stouffer–
Liptak correction, and (4) correcting for multiple testing
with the one-step Šidák correction. Significant regions were
identified as those with at least two probes and a corrected
P value < 0.05.
Second, we implemented a sliding window approach
with multiple window sizes. Previous EWAS have re-
ported DMRs that span either a few hundred or a few
thousand base pairs [62]. As is it unlikely that every
DMR will contain exactly the same number of probes or
have the same genomic span, partly due to the irregular
distribution of 450 K probes across the genome [63],
multiple window sizes were used (100, 200, 500, 1000,
2000, 5000 bp). For each window a combined P value
was calculated from the individual DMP P values con-
tained, taking into account the correlation between
probes [33]. Each probe on the 450 K array was consid-
ered and all probes within the window extended in both
directions were collated. The correlation coefficients be-
tween each pair of probes in the window and P values
from the EWAS were combined using Brown’s method
for combining non-independent test statistics [33]. To
derive an appropriate multiple testing threshold (based
on 5 % family-wise error), we repeated this procedure on
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the results of the randomly permuted EWASs separately
for each sized window, identified the minimum region P
value for each permutation, and calculated the fifth per-
centile. The set of significant regions was then reduced
into the best non-overlapping set by ranking all regions
by their P value, retaining the most significant, and re-
moving any that overlapped (defined as both regions
containing any common probes), before moving to the
next most significant region, until the bottom of the list
was reached.
Enrichment of regulatory regions
Published 450 K array probe annotations [36] were used
to identify probes located in transcription factor binding
sites or DHSs based on data made publically available as
part of the ENCODE project [3, 35]. The overlap be-
tween regulatory features and DMPs was tested for en-
richment using a two-sided Fisher’s 2 × 2 exact test. The
significance level for enrichment of overlap with
transcription factor binding sites was calculated using a
Bonferroni correction for the 148 different transcription
factor binding sites tested.
Gene ontology analysis
Illumina UCSC gene annotation, which is derived from
the genomic overlap of probes with RefSeq genes or up
to 1500 bp of the transcription start site of a gene, was
used to create a test gene list from the DMPs for path-
way analysis. Where probes were not annotated to any
gene (i.e. in the case of intergenic locations), they were
omitted from this analysis; where probes were annotated
to multiple genes, all were included. A logistic regression
approach was used to test if genes in this list predicted
pathway membership, while controlling for the number
of probes that passed quality control (i.e., were tested)
annotated to each gene. Pathways were downloaded
from the GO website (http://geneontology.org/) and
mapped to genes, including all parent ontology terms.
All genes with at least one 450 K probe annotated and
mapped to at least one GO pathway were considered.
Pathways were filtered to those containing between 10
and 2000 genes. After applying this method to all path-
ways, the list of significant pathways (P < 0.05) was re-
fined by grouping to control for the effect of overlapping
genes. This was achieved by taking the most significant
pathway, and retesting all remaining significant pathways
while controlling additionally for the best term. If the
test genes no longer predicted the pathway, the term
was said to be explained by the more significant pathway,
and hence these pathways were grouped together. This al-
gorithm was repeated, taking the next most significant
term, until all pathways were considered as the most
significant or found to be explained by a more significant
term.
Meta-analysis
All probes with P value < 5 × 10−5 in the phase 1 EWAS
were considered for a meta-analysis with phase 2 and
phase 3 for case–control analysis only. This was per-
formed using the metagen() function in the R package
meta [64], providing the regression coefficients and
standard errors from each individual cohort to calculate
weighted pooled estimates and to test for significance.
Results from both fixed and random effects models are
reported in Additional file 2: Tables S8 and S10; how-
ever, we only considered those from the fixed effect
model because, with only two or three cohorts, estimates
of heterogeneity are poor.
Overlap with schizophrenia GWAS loci
The GWAS regions were defined by the PGC in their
original manuscript [2] and are available for download
from the PGC website (https://www.med.unc.edu/pgc/
results-and-downloads). Briefly, these were identified by
performing a “clumping” procedure on the GWAS P
values to collapse multiple correlated signals (due to LD)
surrounding the index SNP (i.e., with the smallest P value)
into a single associated region. To define 108 physically
distinct loci, those within 250 kb of each other were sub-
sequently merged to obtain the final set of GWAS regions.
The outermost SNPs of each associated region define the
start and stop parameters of the region. Using the set of
105 autosomal schizophrenia-associated genomic loci we
used Brown’s method [33] to calculate a combined P value
across all 450 K probes located within each region. This
used the P values from both the case–control and PRS
EWAS and correlation coefficients between all pairs of
probes calculated from the DNA methylation values. This
methodology was repeated with the 5000 random permu-
tations we generated. Empirical P values for each region
were calculated by counting how many of the per-
mutations had more significant P values than the true
combined P value and dividing by the total number of per-
mutations performed.
Co-localization analyses
Schizophrenia-associated genomic loci were taken as the
105 autosomal regions published as part of the PGC
mega-analysis [2]. Given our definition of cis mQTLs
(i.e., associations between SNPs and DNA methylation
probes within 500 kb), all DNA methylation sites located
within 500 kb of these regions were identified and cis
mQTL analysis was performed using MatrixEQTL [65].
An additive linear model was fitted to test if the number
of alleles (coded 0, 1, or 2) predicted DNA methylation
(beta value 0–100) at each site, including covariates for
age, sex, and the first two PCs from the genotype data.
Co-localization analysis was performed as previously
described [46] using the R coloc package (http://cran.r-
Hannon et al. Genome Biology  (2016) 17:176 Page 13 of 16
project.org/web/packages/coloc) for each DNA methyla-
tion site within each region. From both the PGC schizo-
phrenia GWAS data and our mQTL results we inputted
the regression coefficients, their variances, and the SNP
minor allele frequencies, and the prior probabilities were
left as their default values. This methodology quantifies
the support across the results of each GWAS for five
hypotheses by calculating the posterior probabilities,
denoted as PPi for hypothesis Hi:
H0: there exist no causal variants for either trait;
H1: there exists a causal variant for one trait only,
schizophrenia;
H2: there exists a causal variant for one trait only,
DNA methylation;
H3: there exist two distinct causal variants, one for each
trait;
H4: there exists a single causal variant common to both
traits.
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